Norbert Galldiks, Jana-Marie Peplinski, Manuel Kraft, Philipp Lohmann, Jan-Michael Werner
{"title":"The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment.","authors":"Norbert Galldiks, Jana-Marie Peplinski, Manuel Kraft, Philipp Lohmann, Jan-Michael Werner","doi":"10.1097/WCO.0000000000001425","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To summarize the role of diagnostic amino acid PET in the era of checkpoint inhibitors and targeted therapies for brain tumor treatment.</p><p><strong>Recent findings: </strong>Amino acid PET, particularly O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET, has shown promise in distinguishing treatment-related changes such as pseudoprogression and pseudoresponse from true tumor relapse in patients receiving immunotherapy or targeted therapies for brain metastases and gliomas, often outperforming conventional MRI. Additionally, serial amino acid PET imaging has demonstrated potential in early response assessment following these agents.</p><p><strong>Summary: </strong>Larger prospective trials with a higher number of patients are still needed to validate the clinical impact of amino acid PET when immunotherapy or targeted therapies are used for brain tumor therapy.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WCO.0000000000001425","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: To summarize the role of diagnostic amino acid PET in the era of checkpoint inhibitors and targeted therapies for brain tumor treatment.
Recent findings: Amino acid PET, particularly O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET, has shown promise in distinguishing treatment-related changes such as pseudoprogression and pseudoresponse from true tumor relapse in patients receiving immunotherapy or targeted therapies for brain metastases and gliomas, often outperforming conventional MRI. Additionally, serial amino acid PET imaging has demonstrated potential in early response assessment following these agents.
Summary: Larger prospective trials with a higher number of patients are still needed to validate the clinical impact of amino acid PET when immunotherapy or targeted therapies are used for brain tumor therapy.
综述目的：总结诊断性氨基酸PET在检查点抑制剂和靶向治疗时代在脑肿瘤治疗中的作用。最近的发现：氨基酸PET，特别是O-（2-[18F]-氟乙基）- l -酪氨酸（FET） PET，在接受免疫治疗或脑转移瘤和胶质瘤靶向治疗的患者中，在区分治疗相关的变化，如假进展和假反应与真正的肿瘤复发方面显示出了希望，通常优于传统的MRI。此外，序列氨基酸PET成像在这些药物后的早期反应评估中显示出潜力。总结：当免疫治疗或靶向治疗用于脑肿瘤治疗时，仍需要更大规模的前瞻性试验和更多的患者来验证氨基酸PET的临床影响。
期刊介绍：
Current Opinion in Neurology is a highly regarded journal offering insightful editorials and on-the-mark invited reviews; covering key subjects such as cerebrovascular disease, developmental disorders, neuroimaging and demyelinating diseases. Published bimonthly, each issue of Current Opinion in Neurology introduces world renowned guest editors and internationally recognized academics within the neurology field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
